Increased HPV Incidence To Drive Global HPV Testing Market 2015-2019

Dublin-based market analysis firm Research and Markets has announced the release of a major new 70 page report: “Global HPV Testing Market 2015-2019,” projecting that the global Human Papilloma Virus (HPV) testing market will grow at a Compound Annual Growth Rate (CAGR) of 16.17% over the period 2014-2019.

The HPV category refers to a group of more than 200 related viruses commonly causing infections that do not manifest obvious symptoms, and among which are more than 40 HPV variants that nevertheless cause highly contagious diseases that are primarily transmitted through direct sexual contact, and that infect both male and female genitals. Other types of HPV cause non-genital warts that are not sexually transmitted. While most HPV infections are harmless and heal on their own, the high-risk types of genital HPV can be persistent and cause cervical, penile, anal, vaginal, and oropharyngeal cancers. Consequently, many sexually active individuals who have multiple partners undergo regular HPV tests as a preventive measure. HPV tests help detect the viral genetic material in a cell sample taken from the cervix.

To calculate the market size, the author of Global HPV Testing Market 2015-2019 uses revenue generated from sales of HPV testing kits and detection systems in markets segmented among three regions of the globe: the Americas, APAC, and EMEA.

HPV and Pap tests also help detect cervical cancer in women. The Pap test identifies changes in cervical cells caused by HPV infection, while the HPV test proper is used to check for HPV DNA in sample cells, so a physician may advise a patient to undergo both HPV and Pap tests in order to screening for cervical cancer. The report notes that the American Cancer Society, the US Preventive Services Task Force, the American Society for Clinical Pathology, and the American Society for Colposcopy and Cervical Pathology have all provided guidelines for the testing of cervical cancer in women in the US, recommending that women aged between 30 and 65 should undergo Pap and HPV co-testing every five years, or get a Pap test every three years.

According to the report, HPV is now the most widespread STD in both men and women, and an HPV infection can lead to cervical, vulvar, or vaginal cancer in women, and to penile cancer in men. An estimated 20-million people are currently affected with HPV In the US, with more than six-million individuals becoming newly infected each year. The author cites research revealing that HPV is commonly transmitted through unprotected sexual contact, with factors such as contact with infected skin, genital fluids, or lesions responsible for development of HPV infections. And while lower-risk HPV infection does not lead to cancer, it still can cause condylomata acuminata on or around the genitals, anus, mouth, or throat, with HPV types 6 and 11 for example accounting for 90 percent of genital warts cases. However, the high-risk infections, especially HPV types 16 and 18, are responsible for most HPV-related cancers.

Further, the report states that a lack of awareness of HPV and its diagnostic kits among people has a negative impact on growth of the testing market.

The report, Global HPV Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts, and covers the market landscape and its growth prospects in the coming years, including a discussion of the key vendors operating in this market.

Key questions answered in this report include:
– What will the market size be in 2019 and what will the growth rate be?
– What are the key market trends?
– What is driving this market?
– What are the challenges to market growth?
– Who are the key vendors in this market space?

The author recognizes the following companies as the key players in the global HPV testing market: Abbott Diagnostics, Hologic, Qiagen and Roche Diagnostics. Other prominent vendors in the market are: Arbor Vita, Becton, Dickinson and Company, Cepheid, Delphi Bioscience, DiaCarta, Diasorin, Fujirebio, Genera Biosystems, IncellDx, OralDNA Labs, Quest Diagnostics, Seegene, Trovagene and Ventana Medical Systems

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry, and the report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Report Formats, Pricing, And Ordering Information

Electronic (PDF) – Single User USD 2,500
Electronic (PDF) – 1 – 5 Users USD 3,000
Electronic (PDF) – Site License USD 4,000
Electronic (PDF) – Enterprisewide USD 10,000

To order online, visit:
http://www.researchandmarkets.com/reports/3287781

To order by Fax, use the order form printable from the Web page and Fax it to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

To order by post – print the order form and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Web Addresses:
http://www.researchandmarkets.com/reports/3287781
http://www.researchandmarkets.com/research/2s2746/global_hpv

For more information, visit
http://www.researchandmarkets.com/research/2s2746/global_hpv

SOURCE Research and Markets

Tagged .

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles research and development for the news site, particularly pertaining to technology.

Leave a Comment

Your email address will not be published. Required fields are marked *